Bank of America Securities analyst Alec Stranahan maintained a Buy rating on Beam Therapeutics (BEAM – Research Report) yesterday and set a price target of $43.00. The company’s shares closed yesterday at $17.24.

According to TipRanks, Stranahan is an analyst with an average return of -12.1% and a 34.60% success rate. Stranahan covers the Healthcare sector, focusing on stocks such as Beam Therapeutics, Candel Therapeutics, and Novavax.

In addition to Bank of America Securities, Beam Therapeutics also received a Buy from JonesTrading’s Soumit Roy in a report issued on May 8. However, on May 7, Barclays maintained a Hold rating on Beam Therapeutics (NASDAQ: BEAM).

The company has a one-year high of $35.25 and a one-year low of $13.53. Currently, Beam Therapeutics has an average volume of 2.44M.